Literature DB >> 2104086

Review article: hypoxia and hepatic drug metabolism--clinical implications.

P W Angus1, D J Morgan, R A Smallwood.   

Abstract

Most major pathways of hepatic drug metabolism are dependent on oxygen. Hepatic mixed-function oxidases use oxygen directly as a substrate, while many other enzyme systems are indirectly dependent on oxygen for the generation of essential co-factors, such as NAD+ and ATP. Studies in vitro show that many of these oxygen-dependent reactions are impaired by relatively minor reductions in oxygen supply, of a magnitude likely to be encountered in vivo. Phase I metabolism by mixed-function oxidases appears to be more sensitive to hypoxia than phase II drug conjugation, although the oxygen requirements of conjugation reactions, such as glucuronidation, may be greatly enhanced by poor nutrition or fasting. Studies in humans are few, but in general they affirm the potential importance of the effects of hypoxaemic states on hepatic drug elimination. On present evidence, special care should be taken in hypoxic patients with drugs extensively metabolized by the liver, particularly those which have a low therapeutic ratio.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2104086     DOI: 10.1111/j.1365-2036.1990.tb00466.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  6 in total

Review 1.  Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment.

Authors:  Andrew H Talal; Charles S Venuto; Islam Younis
Journal:  Clin Pharmacol Drug Dev       Date:  2017-03

2.  The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis.

Authors:  D G Le Couteur; A J McLean
Journal:  Clin Pharmacokinet       Date:  1998-05       Impact factor: 6.447

3.  Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m).

Authors:  Michael Streit; Christoph Göggelmann; Christoph Dehnert; Jürgen Burhenne; Klaus-Dieter Riedel; Elmar Menold; Gerd Mikus; Peter Bärtsch; Walter E Haefeli
Journal:  Eur J Clin Pharmacol       Date:  2005-02-04       Impact factor: 2.953

4.  Primary cultures of rat hepatocytes in hollow fiber chambers.

Authors:  H O Jauregui; S Naik; H Santangini; J Pan; D Trenkler; C Mullon
Journal:  In Vitro Cell Dev Biol Anim       Date:  1994-01       Impact factor: 2.416

5.  Analgesics in patients with hepatic impairment: pharmacology and clinical implications.

Authors:  Marija Bosilkovska; Bernhard Walder; Marie Besson; Youssef Daali; Jules Desmeules
Journal:  Drugs       Date:  2012-08-20       Impact factor: 9.546

6.  Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study.

Authors:  Tang-Hsiu Huang; Chin-Wei Kuo; Chian-Wei Chen; Yau-Lin Tseng; Chao-Liang Wu; Sheng-Hsiang Lin
Journal:  BMC Pulm Med       Date:  2021-05-15       Impact factor: 3.317

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.